The trajectory of companies tied to Viagra's past presents a intricate investment landscape. While the initial success generated substantial gains, generic alternatives have significantly diminished revenue. Investing in related pharmaceutical companies now requires a discerning assessment of patent rights , evolving medical changes, and the potent